Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | PDE4A | P27815 | 3/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5941294 | 1.00 | TNF (0.69) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL6703914 | 1.00 | TNF (0.69) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL6095455 | 0.93 | MEN1 (0.60) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL6099978 | 0.93 | PDE4A (0.71) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL825454 | 0.93 | PDE4A (0.71) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL9924689 | 0.92 | TP53 (0.67) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL8436473 | 0.92 | PDE4A (0.70) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL8436482 | 0.92 | PDE4A (0.70) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL5941456 | 0.91 | PDE4A (0.69) | TNFMEN1KMT2ATP53MAPT | |
| SCHEMBL29840774 | 0.91 | PDE4A (0.69) | TNFMEN1KMT2ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247296-A1 | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | CELGENE CORPORATION | 2006-11-02 | — | — | US | claimed |
| EP-1581205-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING (+)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040167199-A1 | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | CELGENE CORPORATION | 2004-08-26 | — | — | US | claimed |
| WO-2004045597-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING (+)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | claimed |
| EP-2583098-B1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| CN-103026229-A | Biomarkers for the treatment of psoriasis | CELGENE CORP | 2013-04-03 | — | — | CN | disclosed |
| US-20090010886-A1 | Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione | CELGENE CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080138295-A1 | Bechet's disease using cyclopropyl-N-carboxamide | CELGENE COPORATION | 2008-06-12 | — | — | US | disclosed |
| CN-1984652-A | Using methods and compositions comprising selective cytokine inhibitory drugs for treatment and management of myeloproliferative diseases | CELGENE CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1984651-A | Methods and compositions for treatment and management of cancer and other diseases using selective cytokine inhibitory drugs | CELGENE CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1972684-A | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | CELGENE CORP (US) | 2007-05-30 | — | — | CN | disclosed |
| EP-1035848-B1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | CALGENE CORPORATION | 2001-12-06 | — | — | US | disclosed |
| US-6214857-B1 | REDUCES TUMOR NECROSIS FACTOR LEVELS | CELGENE CORPORATION | 2001-04-10 | — | — | US | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5703098-A | INHIBITORS OF CYTOKINES INCLUDING TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167199-A1 | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | PDE4A, PDE3A, PDE2A | TNF 12/4885MEN1 3742/4885KMT2A 4038/4885 |
| US-20090010886-A1 | Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione | IL2, MCL1, IL1A | TNF 185/4885MEN1 389/4885KMT2A 1703/4885 |
| US-20080138295-A1 | Bechet's disease using cyclopropyl-N-carboxamide | IL2, TNF, FGF2 | TNF 2/4885MEN1 1111/4885KMT2A 1325/4885 |
| US-20060247296-A1 | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | PDE4A, PDE3A, PDE2A | TNF 11/4885MEN1 2680/4885KMT2A 4347/4885 |
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | PDE3A, PDE2A, PDE3B | TNF 8/4885MEN1 4191/4885KMT2A 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.